Published in Br J Cancer on May 06, 2003
Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal (2011) 1.32
Unusual DNA binding modes for metal anticancer complexes. Biochimie (2009) 0.95
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Invest New Drugs (2014) 0.94
Arene-Ru(II)-chloroquine complexes interact with DNA, induce apoptosis on human lymphoid cell lines and display low toxicity to normal mammalian cells. J Inorg Biochem (2010) 0.91
Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells. Cell Biol Toxicol (2013) 0.86
Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles. Inorg Chem (2013) 0.85
Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry. J Biol Inorg Chem (2010) 0.82
Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process. J Biol Inorg Chem (2015) 0.76
Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution. J Biol Inorg Chem (2007) 0.76
Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties. Int J Mol Sci (2016) 0.75
Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues. Biometals (2016) 0.75
The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure. J Biol Inorg Chem (2015) 0.75
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 40.02
1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem (1997) 3.52
Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest (1994) 3.51
Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest (1997) 3.39
Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst (1998) 2.50
Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol (1996) 2.46
Nitric oxide synthase activity in human gynecological cancer. Cancer Res (1994) 2.27
The multifaceted roles of nitric oxide in cancer. Carcinogenesis (1998) 2.19
Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem (1998) 2.11
Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res (1995) 1.92
Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res (1997) 1.71
Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev (1999) 1.61
Nitric oxide and angiogenesis. J Neurooncol (2001) 1.44
Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol (1997) 1.31
Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer (2002) 1.27
Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol (1999) 1.22
Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer (1998) 1.21
Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer (2000) 1.08
Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer (1999) 1.08
The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J (2001) 1.01
The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. J Biol Chem (1994) 0.98
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. Br J Cancer (2002) 0.91
The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway. Arch Biochem Biophys (2002) 0.89
Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red. Crit Care Med (1999) 0.89
Drug control of solid tumour metastases: a critical view. Anticancer Res (1999) 0.88
Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther (2000) 0.88
Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. Eur J Biochem (2002) 0.87
Mechanistic studies on AMD6221: a ruthenium-based nitric oxide scavenger. Biochem Biophys Res Commun (2002) 0.84
Water-Soluble Ruthenium(III)-Dimethyl Sulfoxide Complexes: Chemical Behaviour and Pharmaceutical Properties. Met Based Drugs (1994) 0.81
The effects of chronic nitric oxide synthase suppression on glioma pathophysiology. Br J Neurosurg (2000) 0.81
Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media. J Biol Inorg Chem (2001) 0.81
Use of nitric oxide synthase inhibitors for the treatment of inflammatory disease and pain. IDrugs (2001) 0.81
Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and HInd trans-[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS. J Biol Inorg Chem (2001) 0.79
Nitric oxide modulates the angiogenic phenotype of middle-T transformed endothelial cells. Int J Biochem Cell Biol (2001) 0.79
Ruthenium complexes as nitric oxide scavengers: a potential therapeutic approach to nitric oxide-mediated diseases. Br J Pharmacol (1997) 0.78
Nitrogen monoxide-related disease and nitrogen monoxide scavengers as potential drugs. Met Ions Biol Syst (1999) 0.78
Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol (1992) 5.04
Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest (1997) 3.39
VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol (1998) 2.71
Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst (1998) 2.50
Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol (1996) 2.46
Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem (1998) 2.11
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst (1995) 2.07
Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. J Med Chem (2000) 1.87
Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst (1982) 1.85
Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer (1999) 1.79
An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res (1997) 1.63
Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci U S A (1990) 1.57
c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci U S A (1999) 1.49
The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer (2000) 1.33
In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest (1991) 1.31
Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst (1982) 1.29
Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. J Inorg Biochem (2011) 1.29
HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene (1996) 1.18
Role of soluble mediators in angiogenesis. Eur J Cancer (1996) 1.17
The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J (2000) 1.12
B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF-2 effects. Br J Pharmacol (1998) 1.07
Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res (1988) 1.06
In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther (1999) 1.04
The activin-binding protein follistatin regulates autocrine endothelial cell activity and induces angiogenesis. Lab Invest (1997) 1.03
Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice. Pharmacol Toxicol (2000) 1.02
I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood (2000) 1.01
Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem Biophys Res Commun (1999) 1.01
The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J (2001) 1.01
Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology (1997) 1.00
Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. Bioorg Med Chem (1999) 1.00
Theoretical and experimental study of DNA helix-coil transition in acidic and alkaline medium. J Biomol Struct Dyn (1994) 1.00
Use of cylindrical titanium mesh and locking plates in anterior cervical fusion. Technical note. J Neurosurg (2001) 1.00
Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol (1995) 0.99
Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. Clin Cancer Res (1999) 0.99
Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans (2007) 0.99
Soluble N-cadherin fragment promotes angiogenesis. Clin Exp Metastasis (2006) 0.99
Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur J Endocrinol (2000) 0.98
The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. J Biol Chem (1994) 0.98
The tachykinin NK1 receptor mediates the migration-promoting effect of substance P on human skin fibroblasts in culture. Naunyn Schmiedebergs Arch Pharmacol (1996) 0.98
Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood (2000) 0.98
Cell-mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis. J Vasc Res (2001) 0.97
In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. J Inorg Biochem (2009) 0.96
Angiogenesis and neoplastic progression in vitro. J Natl Cancer Inst (1982) 0.94
An electromechanical model of cardiac tissue: constitutive issues and electrophysiological effects. Prog Biophys Mol Biol (2008) 0.94
Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest (2007) 0.94
Pharmacological Effects of the Ruthenium Complex NAMI-A Given Orally to CBA Mice With MCa Mammary Carcinoma. Met Based Drugs (2001) 0.93
Crystal structure of the complex between carboxypeptidase A and the biproduct analog inhibitor L-benzylsuccinate at 2.0 A resolution. J Mol Biol (1992) 0.93
Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab Invest (1998) 0.92
FGF-2 overexpression opposes the beta amyloid toxic injuries to the vascular endothelium. Cell Death Differ (2006) 0.91
Expression and regulation of endothelin-1 and its receptors in human penile smooth muscle cells. Mol Hum Reprod (2002) 0.91
Comparison of the Antiproliferative Activity of Two Antitumour Ruthenium(III) Complexes With Their Apotransferrin and Transferrin-Bound Forms in a Human Colon Cancer Cell Line. Met Based Drugs (1996) 0.91
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. Br J Cancer (2002) 0.91
Interactions of two cytotoxic organotin(IV) compounds with calf thymus DNA. J Inorg Biochem (2001) 0.90
Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. Mol Biol Cell (1999) 0.90
DNA as a possible target for antitumor ruthenium(III) complexes. Arch Biochem Biophys (2000) 0.90
High-resolution structure of the complex between carboxypeptidase A and L-phenyl lactate. Acta Crystallogr D Biol Crystallogr (1993) 0.89
Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment. Cell Mol Life Sci (2005) 0.89
Activation of MAPKs in proximal tubule cells from spontaneously hypertensive and control Wistar-Kyoto rats. Hypertension (2000) 0.89
Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ (1996) 0.89
ETB receptors promote proliferation and migration of endothelial cells. J Cardiovasc Pharmacol (1995) 0.89
Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion. J Pharmacol Exp Ther (2005) 0.89
Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. Biochemistry (1997) 0.88
A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin. Eur J Biochem (2000) 0.88
Effects of some ruthenium chelates on MCa mammary carcinoma and on TLX5 lymphoma in mice. Anticancer Res (1993) 0.88
Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Cancer Res (1995) 0.88
Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther (2000) 0.88
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin. Invest New Drugs (2003) 0.88
Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms. Eur J Cancer Clin Oncol (1984) 0.88
Quantitative RT-PCR assay for VEGF mRNA in human tumors of the kidney. Int J Biol Markers (2000) 0.87
Testosterone and sexual activity. J Endocrinol Invest (2005) 0.87
alpha(1D)-adrenoceptors cause endothelium-dependent vasodilatation in the rat mesenteric vascular bed. J Pharmacol Exp Ther (2001) 0.87
Exogenous BH4/Bcl-2 peptide reverts coronary endothelial cell apoptosis induced by oxidative stress. J Vasc Res (2004) 0.86
Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat. Int J Impot Res (2007) 0.86
Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res (1999) 0.85
Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: biological activity and intracellular fate of human recombinant M(r) 24,000 bFGF. J Cell Physiol (1994) 0.85
Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J Clin Invest (1993) 0.85
[Cicatricial stenosis of the small intestine of ischemic origin: 7 cases]. Ann Chir (1969) 0.84
Comparative Analysis of [Au(en)(2)] and [Pt(en)(2)] non Covalent Binding to Calf Thymus DNA. Met Based Drugs (2000) 0.84
Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm). J Inorg Biochem (1997) 0.84
Viscoelastic Fitzhugh-Nagumo models. Phys Rev E Stat Nonlin Soft Matter Phys (2005) 0.84
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy. Diabetes Metab (2008) 0.83
Blockade of adenosine receptors unmasks a stimulatory effect of ATP on cardiac contractility. Br J Pharmacol (1993) 0.83
Peripheral regulatory mechanisms in erection. Int J Androl (2005) 0.83
Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mol Hum Reprod (2005) 0.83
T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy. Biologics (2008) 0.83
Plasminogen activators (urokinase) mediate neovascularization: possible role in tumor angiogenesis. Semin Thromb Hemost (1986) 0.83